Kazia Therapeutics Limited (KZIA) 10-Year Financial Performance & Capital Metrics

KZIA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutKazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Show more

Revenue $42K -98.2%
EBITDA -$13M +50.1%
Net Income -$21M +22.7%
EPS (Diluted) -18.90 +65.6%
Gross Margin 100%
EBITDA Margin -31626.19% -2644.8%
Operating Margin -33850% -2644.9%
Net Margin -49290.48% -4148.4%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Sales declining 46.8% over 5 years
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-7.23%

5Y-46.83%

3Y61.34%

TTM-83.52%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-8.49%

EPS CAGR

10Y-

5Y-

3Y-

TTM52.4%

ROCE

10Y Avg-82.78%

5Y Avg-132.34%

3Y Avg-223.1%

Latest-

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	4.07M	8.79M	13.11K	1.56K	988.11K	15.18M	10K	555	2.31M	42K
Revenue Growth %	44.74%	1.16%	-1%	-0.88%	630.38%	14.37%	-1%	-0.94%	4157.56%	-0.98%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	4.07M	8.79M	13.11K	1.56K	988.11K	15.18M	10K	555	2.31M	42K
Gross Margin %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	44.74%	1.16%	-1%	-0.88%	630.38%	14.37%	-1%	-0.94%	4157.56%	-0.98%
Operating Expenses+	15.64M	19.66M	14.69M	10.25M	13.18M	21.56M	25.41M	24.12M	30.77M	14.26M
OpEx % of Revenue	3.84%	2.24%	1120.46%	6551.44%	13.34%	1.42%	2540.9%	43467.61%	13.33%	339.5%
Selling, General & Admin	5.76M	8.53M	5.6M	3.79M	3.69M	7.02M	5.24M	8.58M	13.56M	8.72M
SG&A % of Revenue	1.42%	0.97%	427.07%	2419.17%	3.73%	0.46%	524%	15464.89%	5.88%	207.62%
Research & Development	9.89M	11.14M	9.77M	6.48M	9.49M	14.54M	20.17M	15.56M	17.38M	7.33M
R&D % of Revenue	2.43%	1.27%	745.65%	4138.02%	9.61%	0.96%	2016.9%	28043.37%	7.53%	174.43%
Other Operating Expenses	0	0	3.67M	-9K	0	-2K	0	-22.56K	-173K	-1.79M
Operating Income+	-12.77M	-10.85M	-12.49M	-8.38M	-12.2M	-6.38M	-25.4M	-24.12M	-28.46M	-14.22M
Operating Margin %	-3.14%	-1.23%	-952.62%	-5354.63%	-12.34%	-0.42%	-2539.9%	-43466.61%	-12.33%	-338.5%
Operating Income Growth %	-0.57%	0.15%	-0.15%	0.33%	-0.46%	0.48%	-2.98%	0.05%	-0.18%	0.5%
EBITDA+	-12.13M	-9.44M	-10.94M	-7.3M	-11.11M	-5.11M	-23.53M	-22.25M	-26.59M	-13.28M
EBITDA Margin %	-2.98%	-1.07%	-834.76%	-4661.98%	-11.25%	-0.34%	-2353%	-40098.21%	-11.52%	-316.26%
EBITDA Growth %	-0.6%	0.22%	-0.16%	0.33%	-0.52%	0.54%	-3.6%	0.05%	-0.19%	0.5%
D&A (Non-Cash Add-back)	642.64K	1.41M	1.54M	1.08M	1.08M	1.26M	1.87M	1.87M	1.87M	934K
EBIT	-12.36M	-10.85M	-14.57M	-8.79M	-12.19M	-6.38M	-25.38M	-24.15M	-28.46M	-14.22M
Net Interest Income+	0	0	0	-2.09M	66K	42.24K	0	22.84K	12K	72K
Interest Income	406K	276	119K	100K	66K	42.24K	2.09K	22.84K	12K	72K
Interest Expense	0	0	0	2.19M	0	0	2.09K	0	0	0
Other Income/Expense	227.97K	7.87K	6.02M	-1.75M	-569.58K	-2.53M	17K	3.41M	1.41M	-8.23M
Pretax Income+	-12.15M	-10.87M	-6.34M	-10.57M	-12.77M	-8.9M	-25.38M	-20.74M	-27.05M	-22.45M
Pretax Margin %	-2.99%	-1.24%	-483.98%	-6752.72%	-12.92%	-0.59%	-2538.2%	-37362.65%	-11.72%	-534.48%
Income Tax+	2.77M	-198.54K	-305K	-298K	-298.19K	-484K	-368K	-271.09K	-271K	-1.75M
Effective Tax Rate %	0.99%	0.98%	0.95%	0.97%	0.98%	0.95%	0.99%	0.99%	0.99%	0.92%
Net Income+	-12.06M	-10.67M	-6.04M	-10.27M	-12.47M	-8.42M	-25.01M	-20.47M	-26.78M	-20.7M
Net Margin %	-2.96%	-1.21%	-460.71%	-6562.3%	-12.62%	-0.55%	-2501.4%	-36874.2%	-11.6%	-492.9%
Net Income Growth %	-0.69%	0.12%	0.43%	-0.7%	-0.21%	0.32%	-1.97%	0.18%	-0.31%	0.23%
Net Income (Continuing)	-12.15M	-10.67M	-6.04M	-10.27M	-12.47M	-8.42M	-25.01M	-20.47M	-26.78M	-20.7M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-135.20	-109.30	-59.80	-85.60	-80.00	-35.80	-95.00	-55.00	-55.00	-18.90
EPS Growth %	0.06%	0.19%	0.45%	-0.43%	0.07%	0.55%	-1.65%	0.42%	0%	0.66%
EPS (Basic)	-135.20	-109.30	-59.80	-85.60	-80.00	-35.80	-95.00	-55.00	-55.00	-18.90
Diluted Shares Outstanding	89.2K	97.63K	100.96K	120.01K	152.46K	235.4K	265K	368.6K	479.6K	1.1M
Basic Shares Outstanding	89.2K	97.63K	100.96K	120.01K	152.46K	235.4K	265K	368.6K	479.6K	1.1M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	34.09M	19.48M	9.26M	7.51M	10.65M	29.39M	9.45M	10.77M	6.14M	4.93M
Cash & Short-Term Investments	33.45M	14.45M	5.96M	5.43M	8.76M	27.59M	7.36M	5.24M	1.66M	4.34M
Cash Only	33.45M	14.45M	5.96M	5.43M	8.76M	27.59M	7.36M	5.24M	1.66M	4.34M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	91K	5.07K	1.13K	0	439	0	51K	105K	133K	90K
Days Sales Outstanding	8.16	0.21	31.47	-	0.16	-	1.86K	69.05K	21.03	782.14
Inventory	434K	0	0	-1.55M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	4.26M	0	0	1.19M	84.36K	0	0	0	0
Total Non-Current Assets+	1.43M	16.43M	18.91M	13.66M	12.41M	28.7M	26.44M	17.31M	15.44M	1.13M
Property, Plant & Equipment	592K	489.61K	1K	0	0	0	0	0	0	0
Fixed Asset Turnover	6.88x	17.95x	13.11x	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	822K	15.92M	14.58M	13.49M	12.41M	22M	19.14M	17.27M	15.4M	1.09M
Long-Term Investments	13K	21.8K	4.33M	168K	0	0	0	0	0	0
Other Non-Current Assets	-1.43M	-16.43M	-18.92M	-13.66M	0	6.69M	7.3M	43K	40K	40K
Total Assets+	35.52M	35.91M	28.18M	21.18M	23.06M	58.09M	35.89M	28.08M	21.59M	6.06M
Asset Turnover	0.11x	0.24x	0.00x	0.00x	0.04x	0.26x	0.00x	0.00x	0.11x	0.01x
Asset Growth %	-0.23%	0.01%	-0.22%	-0.25%	0.09%	1.52%	-0.38%	-0.22%	-0.23%	-0.72%
Total Current Liabilities+	1.43M	5.38M	3.89M	1.9M	5.07M	8.33M	6.73M	7.57M	25.8M	14.05M
Accounts Payable	512K	1.25M	1.41M	1.05M	1.69M	1.89M	1.52M	857K	4.55M	5.64M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	1.84M	1.8M	634K	396K
Deferred Revenue (Current)	900K	41K	138K	0	0	0	0	0	0	0
Other Current Liabilities	132K	3.36M	1.68M	0	1.58M	3.16M	1.13M	1.44M	10.1M	3.54M
Current Ratio	23.81x	3.62x	2.38x	3.96x	2.10x	3.53x	1.40x	1.42x	0.24x	0.35x
Quick Ratio	23.50x	3.62x	2.38x	4.77x	2.10x	3.53x	1.40x	1.42x	0.24x	0.35x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	154K	5.19M	5.05M	5.08M	3.87M	11.91M	10.89M	8.47M	5.8M	309K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	4.31M	4.01M	3.71M	3.41M	0	2.56M	2.29M	2.02M	272K
Other Non-Current Liabilities	154K	874.31K	1.04M	5.08M	458K	11.91M	8.33M	6.18M	3.79M	37K
Total Liabilities	1.59M	10.57M	8.93M	6.98M	8.94M	20.24M	17.61M	16.03M	31.6M	14.36M
Total Debt+	10K	10K	84K	0	0	0	1.84M	1.8M	634K	396K
Net Debt	-33.44M	-14.44M	-5.87M	-5.43M	-8.76M	-27.59M	-5.52M	-3.44M	-1.02M	-3.95M
Debt / Equity	0.00x	0.00x	0.00x	-	-	-	0.10x	0.15x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-3.83x	-	-	-12129.42x	-	-	-
Total Equity+	33.93M	25.34M	19.24M	14.2M	14.13M	37.85M	18.27M	12.05M	-10.02M	-8.3M
Equity Growth %	-0.24%	-0.25%	-0.24%	-0.26%	-0%	1.68%	-0.52%	-0.34%	-1.83%	0.17%
Book Value per Share	380.38	259.52	190.59	118.28	92.65	160.79	68.96	32.69	-20.89	-7.58
Total Shareholders' Equity	33.93M	25.34M	19.24M	14.2M	14.13M	37.85M	18.27M	12.05M	-10.02M	-8.3M
Common Stock	191.3M	193.77M	31.58M	36.64M	48.78M	80.29M	84.48M	97.45M	101.64M	123.05M
Retained Earnings	-160.51M	-170.96M	-14.64M	-24.95M	-36.19M	-44.2M	-68.62M	-89.08M	-115.13M	-134.83M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.42M	1.93M	1.84M	2.04M	1.07M	1.76M	2.41M	3.68M	3.48M	3.1M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-11.98M	-11.43M	-8.66M	-6.71M	-8.81M	-9.11M	-22.76M	-15.16M	-9.58M	-13.28M
Operating CF Margin %	-2.94%	-1.3%	-660.74%	-4290.1%	-8.92%	-0.6%	-2276.2%	-27308.11%	-4.15%	-316.14%
Operating CF Growth %	-1.08%	0.05%	0.24%	0.22%	-0.31%	-0.03%	-1.5%	0.33%	0.37%	-0.39%
Net Income	-12.15M	-10.67M	-6.04M	-10.27M	-12.47M	-8.42M	-25.01M	-20.46M	-26.78M	-20.7M
Depreciation & Amortization	643K	1.41M	1.55M	1.08M	1.08M	1.26M	1.87M	1.87M	1.87M	934K
Stock-Based Compensation	372K	517K	165K	246K	262K	637K	1.68M	1.16M	533K	653K
Deferred Taxes	-225K	3.51M	3.97M	1.81M	168K	0	0	0	0	0
Other Non-Cash Items	100K	1.33M	-9.84M	62K	474K	3M	-2.15M	-2.05M	4.79M	8.85M
Working Capital Changes	-715K	-4.02M	1.54M	353K	1.67M	-5.59M	862K	4.33M	10M	-3.01M
Change in Receivables	15K	-4.02M	1.72M	825K	358K	-5.03M	-7K	3.45M	5K	3.8M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-522K	-7.12M	150K	2.36M	0	0	-2.37M	0	0	0
Capital Expenditures	-525K	-11.65K	0	0	0	0	0	0	0	0
CapEx % of Revenue	0.13%	0%	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	3K	-8.6K	150K	2.36M	0	0	0	0	0	0
Cash from Financing+	782K	-17.66K	0	3.82M	12.14M	28.11M	3.73M	12.97M	5.99M	15.98M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-71K	-18K	0	0	1K	0	0	0	0	1.18M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.51M	-11.45M	-8.66M	-6.71M	-8.81M	-9.11M	-22.76M	-15.16M	-9.58M	-13.28M
FCF Margin %	-3.07%	-1.3%	-660.74%	-4290.1%	-8.92%	-0.6%	-2276.2%	-27308.11%	-4.15%	-316.14%
FCF Growth %	-1.14%	0.08%	0.24%	0.22%	-0.31%	-0.03%	-1.5%	0.33%	0.37%	-0.39%
FCF per Share	-140.19	-117.24	-85.79	-55.95	-57.79	-38.70	-85.89	-41.12	-19.98	-12.12
FCF Conversion (FCF/Net Income)	0.99x	1.07x	1.43x	0.65x	0.71x	1.08x	0.91x	0.74x	0.36x	0.64x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-30.81%	-36.01%	-27.09%	-61.43%	-88.05%	-32.4%	-89.14%	-134.97%	-2634.33%	-
Return on Invested Capital (ROIC)	-4002.89%	-143.04%	-77.2%	-56.8%	-129.54%	-61.21%	-165.51%	-169.41%	-	-
Gross Margin	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Margin	-296.29%	-121.42%	-46071.1%	-656230.03%	-1261.75%	-55.46%	-250140%	-3687419.82%	-1160.23%	-49290.48%
Debt / Equity	0.00x	0.00x	0.00x	-	-	-	0.10x	0.15x	-	-
Interest Coverage	-	-	-	-3.83x	-	-	-12129.42x	-	-	-
FCF Conversion	0.99x	1.07x	1.43x	0.65x	0.71x	1.08x	0.91x	0.74x	0.36x	0.64x
Revenue Growth	4474.16%	115.87%	-99.85%	-88.06%	63038.02%	1436.57%	-99.93%	-94.45%	415755.86%	-98.18%

Revenue by Segment

	2021	2024	2025
Licensing Revenue	15.18M	2.3M	-
Licensing Revenue Growth	-	-84.84%	-

Revenue by Geography

	2021	2024	2025
ISRAEL	-	-	42K
ISRAEL Growth	-	-	-
CHINA	10.01M	-	-
CHINA Growth	-	-	-
Swedan	5.18M	-	-
Swedan Growth	-	-	-

Frequently Asked Questions

Growth & Financials

Kazia Therapeutics Limited (KZIA) reported $2.5M in revenue for fiscal year 2025. This represents a 2% increase from $2.5M in 2012.

Kazia Therapeutics Limited (KZIA) saw revenue decline by 98.2% over the past year.

Kazia Therapeutics Limited (KZIA) reported a net loss of $44.1M for fiscal year 2025.

Dividend & Returns

Kazia Therapeutics Limited (KZIA) had negative free cash flow of $20.1M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Kazia Therapeutics Limited (KZIA) 10-Year Financial Performance & Capital Metrics

KZIA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $42K -98.2%
EBITDA -$13M +50.1%
Net Income -$21M +22.7%
EPS (Diluted) -18.90 +65.6%
Gross Margin 100%
EBITDA Margin -31626.19% -2644.8%
Operating Margin -33850% -2644.9%
Net Margin -49290.48% -4148.4%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Sales declining 46.8% over 5 years
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-7.23%

5Y-46.83%

3Y61.34%

TTM-83.52%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-8.49%

EPS CAGR

10Y-

5Y-

3Y-

TTM52.4%

ROCE

10Y Avg-82.78%

5Y Avg-132.34%

3Y Avg-223.1%

Latest-

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	4.07M	8.79M	13.11K	1.56K	988.11K	15.18M	10K	555	2.31M	42K
Revenue Growth %	44.74%	1.16%	-1%	-0.88%	630.38%	14.37%	-1%	-0.94%	4157.56%	-0.98%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	4.07M	8.79M	13.11K	1.56K	988.11K	15.18M	10K	555	2.31M	42K
Gross Margin %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	44.74%	1.16%	-1%	-0.88%	630.38%	14.37%	-1%	-0.94%	4157.56%	-0.98%
Operating Expenses+	15.64M	19.66M	14.69M	10.25M	13.18M	21.56M	25.41M	24.12M	30.77M	14.26M
OpEx % of Revenue	3.84%	2.24%	1120.46%	6551.44%	13.34%	1.42%	2540.9%	43467.61%	13.33%	339.5%
Selling, General & Admin	5.76M	8.53M	5.6M	3.79M	3.69M	7.02M	5.24M	8.58M	13.56M	8.72M
SG&A % of Revenue	1.42%	0.97%	427.07%	2419.17%	3.73%	0.46%	524%	15464.89%	5.88%	207.62%
Research & Development	9.89M	11.14M	9.77M	6.48M	9.49M	14.54M	20.17M	15.56M	17.38M	7.33M
R&D % of Revenue	2.43%	1.27%	745.65%	4138.02%	9.61%	0.96%	2016.9%	28043.37%	7.53%	174.43%
Other Operating Expenses	0	0	3.67M	-9K	0	-2K	0	-22.56K	-173K	-1.79M
Operating Income+	-12.77M	-10.85M	-12.49M	-8.38M	-12.2M	-6.38M	-25.4M	-24.12M	-28.46M	-14.22M
Operating Margin %	-3.14%	-1.23%	-952.62%	-5354.63%	-12.34%	-0.42%	-2539.9%	-43466.61%	-12.33%	-338.5%
Operating Income Growth %	-0.57%	0.15%	-0.15%	0.33%	-0.46%	0.48%	-2.98%	0.05%	-0.18%	0.5%
EBITDA+	-12.13M	-9.44M	-10.94M	-7.3M	-11.11M	-5.11M	-23.53M	-22.25M	-26.59M	-13.28M
EBITDA Margin %	-2.98%	-1.07%	-834.76%	-4661.98%	-11.25%	-0.34%	-2353%	-40098.21%	-11.52%	-316.26%
EBITDA Growth %	-0.6%	0.22%	-0.16%	0.33%	-0.52%	0.54%	-3.6%	0.05%	-0.19%	0.5%
D&A (Non-Cash Add-back)	642.64K	1.41M	1.54M	1.08M	1.08M	1.26M	1.87M	1.87M	1.87M	934K
EBIT	-12.36M	-10.85M	-14.57M	-8.79M	-12.19M	-6.38M	-25.38M	-24.15M	-28.46M	-14.22M
Net Interest Income+	0	0	0	-2.09M	66K	42.24K	0	22.84K	12K	72K
Interest Income	406K	276	119K	100K	66K	42.24K	2.09K	22.84K	12K	72K
Interest Expense	0	0	0	2.19M	0	0	2.09K	0	0	0
Other Income/Expense	227.97K	7.87K	6.02M	-1.75M	-569.58K	-2.53M	17K	3.41M	1.41M	-8.23M
Pretax Income+	-12.15M	-10.87M	-6.34M	-10.57M	-12.77M	-8.9M	-25.38M	-20.74M	-27.05M	-22.45M
Pretax Margin %	-2.99%	-1.24%	-483.98%	-6752.72%	-12.92%	-0.59%	-2538.2%	-37362.65%	-11.72%	-534.48%
Income Tax+	2.77M	-198.54K	-305K	-298K	-298.19K	-484K	-368K	-271.09K	-271K	-1.75M
Effective Tax Rate %	0.99%	0.98%	0.95%	0.97%	0.98%	0.95%	0.99%	0.99%	0.99%	0.92%
Net Income+	-12.06M	-10.67M	-6.04M	-10.27M	-12.47M	-8.42M	-25.01M	-20.47M	-26.78M	-20.7M
Net Margin %	-2.96%	-1.21%	-460.71%	-6562.3%	-12.62%	-0.55%	-2501.4%	-36874.2%	-11.6%	-492.9%
Net Income Growth %	-0.69%	0.12%	0.43%	-0.7%	-0.21%	0.32%	-1.97%	0.18%	-0.31%	0.23%
Net Income (Continuing)	-12.15M	-10.67M	-6.04M	-10.27M	-12.47M	-8.42M	-25.01M	-20.47M	-26.78M	-20.7M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-135.20	-109.30	-59.80	-85.60	-80.00	-35.80	-95.00	-55.00	-55.00	-18.90
EPS Growth %	0.06%	0.19%	0.45%	-0.43%	0.07%	0.55%	-1.65%	0.42%	0%	0.66%
EPS (Basic)	-135.20	-109.30	-59.80	-85.60	-80.00	-35.80	-95.00	-55.00	-55.00	-18.90
Diluted Shares Outstanding	89.2K	97.63K	100.96K	120.01K	152.46K	235.4K	265K	368.6K	479.6K	1.1M
Basic Shares Outstanding	89.2K	97.63K	100.96K	120.01K	152.46K	235.4K	265K	368.6K	479.6K	1.1M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	34.09M	19.48M	9.26M	7.51M	10.65M	29.39M	9.45M	10.77M	6.14M	4.93M
Cash & Short-Term Investments	33.45M	14.45M	5.96M	5.43M	8.76M	27.59M	7.36M	5.24M	1.66M	4.34M
Cash Only	33.45M	14.45M	5.96M	5.43M	8.76M	27.59M	7.36M	5.24M	1.66M	4.34M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	91K	5.07K	1.13K	0	439	0	51K	105K	133K	90K
Days Sales Outstanding	8.16	0.21	31.47	-	0.16	-	1.86K	69.05K	21.03	782.14
Inventory	434K	0	0	-1.55M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	4.26M	0	0	1.19M	84.36K	0	0	0	0
Total Non-Current Assets+	1.43M	16.43M	18.91M	13.66M	12.41M	28.7M	26.44M	17.31M	15.44M	1.13M
Property, Plant & Equipment	592K	489.61K	1K	0	0	0	0	0	0	0
Fixed Asset Turnover	6.88x	17.95x	13.11x	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	822K	15.92M	14.58M	13.49M	12.41M	22M	19.14M	17.27M	15.4M	1.09M
Long-Term Investments	13K	21.8K	4.33M	168K	0	0	0	0	0	0
Other Non-Current Assets	-1.43M	-16.43M	-18.92M	-13.66M	0	6.69M	7.3M	43K	40K	40K
Total Assets+	35.52M	35.91M	28.18M	21.18M	23.06M	58.09M	35.89M	28.08M	21.59M	6.06M
Asset Turnover	0.11x	0.24x	0.00x	0.00x	0.04x	0.26x	0.00x	0.00x	0.11x	0.01x
Asset Growth %	-0.23%	0.01%	-0.22%	-0.25%	0.09%	1.52%	-0.38%	-0.22%	-0.23%	-0.72%
Total Current Liabilities+	1.43M	5.38M	3.89M	1.9M	5.07M	8.33M	6.73M	7.57M	25.8M	14.05M
Accounts Payable	512K	1.25M	1.41M	1.05M	1.69M	1.89M	1.52M	857K	4.55M	5.64M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	1.84M	1.8M	634K	396K
Deferred Revenue (Current)	900K	41K	138K	0	0	0	0	0	0	0
Other Current Liabilities	132K	3.36M	1.68M	0	1.58M	3.16M	1.13M	1.44M	10.1M	3.54M
Current Ratio	23.81x	3.62x	2.38x	3.96x	2.10x	3.53x	1.40x	1.42x	0.24x	0.35x
Quick Ratio	23.50x	3.62x	2.38x	4.77x	2.10x	3.53x	1.40x	1.42x	0.24x	0.35x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	154K	5.19M	5.05M	5.08M	3.87M	11.91M	10.89M	8.47M	5.8M	309K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	4.31M	4.01M	3.71M	3.41M	0	2.56M	2.29M	2.02M	272K
Other Non-Current Liabilities	154K	874.31K	1.04M	5.08M	458K	11.91M	8.33M	6.18M	3.79M	37K
Total Liabilities	1.59M	10.57M	8.93M	6.98M	8.94M	20.24M	17.61M	16.03M	31.6M	14.36M
Total Debt+	10K	10K	84K	0	0	0	1.84M	1.8M	634K	396K
Net Debt	-33.44M	-14.44M	-5.87M	-5.43M	-8.76M	-27.59M	-5.52M	-3.44M	-1.02M	-3.95M
Debt / Equity	0.00x	0.00x	0.00x	-	-	-	0.10x	0.15x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-3.83x	-	-	-12129.42x	-	-	-
Total Equity+	33.93M	25.34M	19.24M	14.2M	14.13M	37.85M	18.27M	12.05M	-10.02M	-8.3M
Equity Growth %	-0.24%	-0.25%	-0.24%	-0.26%	-0%	1.68%	-0.52%	-0.34%	-1.83%	0.17%
Book Value per Share	380.38	259.52	190.59	118.28	92.65	160.79	68.96	32.69	-20.89	-7.58
Total Shareholders' Equity	33.93M	25.34M	19.24M	14.2M	14.13M	37.85M	18.27M	12.05M	-10.02M	-8.3M
Common Stock	191.3M	193.77M	31.58M	36.64M	48.78M	80.29M	84.48M	97.45M	101.64M	123.05M
Retained Earnings	-160.51M	-170.96M	-14.64M	-24.95M	-36.19M	-44.2M	-68.62M	-89.08M	-115.13M	-134.83M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.42M	1.93M	1.84M	2.04M	1.07M	1.76M	2.41M	3.68M	3.48M	3.1M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-11.98M	-11.43M	-8.66M	-6.71M	-8.81M	-9.11M	-22.76M	-15.16M	-9.58M	-13.28M
Operating CF Margin %	-2.94%	-1.3%	-660.74%	-4290.1%	-8.92%	-0.6%	-2276.2%	-27308.11%	-4.15%	-316.14%
Operating CF Growth %	-1.08%	0.05%	0.24%	0.22%	-0.31%	-0.03%	-1.5%	0.33%	0.37%	-0.39%
Net Income	-12.15M	-10.67M	-6.04M	-10.27M	-12.47M	-8.42M	-25.01M	-20.46M	-26.78M	-20.7M
Depreciation & Amortization	643K	1.41M	1.55M	1.08M	1.08M	1.26M	1.87M	1.87M	1.87M	934K
Stock-Based Compensation	372K	517K	165K	246K	262K	637K	1.68M	1.16M	533K	653K
Deferred Taxes	-225K	3.51M	3.97M	1.81M	168K	0	0	0	0	0
Other Non-Cash Items	100K	1.33M	-9.84M	62K	474K	3M	-2.15M	-2.05M	4.79M	8.85M
Working Capital Changes	-715K	-4.02M	1.54M	353K	1.67M	-5.59M	862K	4.33M	10M	-3.01M
Change in Receivables	15K	-4.02M	1.72M	825K	358K	-5.03M	-7K	3.45M	5K	3.8M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-522K	-7.12M	150K	2.36M	0	0	-2.37M	0	0	0
Capital Expenditures	-525K	-11.65K	0	0	0	0	0	0	0	0
CapEx % of Revenue	0.13%	0%	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	3K	-8.6K	150K	2.36M	0	0	0	0	0	0
Cash from Financing+	782K	-17.66K	0	3.82M	12.14M	28.11M	3.73M	12.97M	5.99M	15.98M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-71K	-18K	0	0	1K	0	0	0	0	1.18M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.51M	-11.45M	-8.66M	-6.71M	-8.81M	-9.11M	-22.76M	-15.16M	-9.58M	-13.28M
FCF Margin %	-3.07%	-1.3%	-660.74%	-4290.1%	-8.92%	-0.6%	-2276.2%	-27308.11%	-4.15%	-316.14%
FCF Growth %	-1.14%	0.08%	0.24%	0.22%	-0.31%	-0.03%	-1.5%	0.33%	0.37%	-0.39%
FCF per Share	-140.19	-117.24	-85.79	-55.95	-57.79	-38.70	-85.89	-41.12	-19.98	-12.12
FCF Conversion (FCF/Net Income)	0.99x	1.07x	1.43x	0.65x	0.71x	1.08x	0.91x	0.74x	0.36x	0.64x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-30.81%	-36.01%	-27.09%	-61.43%	-88.05%	-32.4%	-89.14%	-134.97%	-2634.33%	-
Return on Invested Capital (ROIC)	-4002.89%	-143.04%	-77.2%	-56.8%	-129.54%	-61.21%	-165.51%	-169.41%	-	-
Gross Margin	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Margin	-296.29%	-121.42%	-46071.1%	-656230.03%	-1261.75%	-55.46%	-250140%	-3687419.82%	-1160.23%	-49290.48%
Debt / Equity	0.00x	0.00x	0.00x	-	-	-	0.10x	0.15x	-	-
Interest Coverage	-	-	-	-3.83x	-	-	-12129.42x	-	-	-
FCF Conversion	0.99x	1.07x	1.43x	0.65x	0.71x	1.08x	0.91x	0.74x	0.36x	0.64x
Revenue Growth	4474.16%	115.87%	-99.85%	-88.06%	63038.02%	1436.57%	-99.93%	-94.45%	415755.86%	-98.18%

Revenue by Segment

	2021	2024	2025
Licensing Revenue	15.18M	2.3M	-
Licensing Revenue Growth	-	-84.84%	-

Revenue by Geography

	2021	2024	2025
ISRAEL	-	-	42K
ISRAEL Growth	-	-	-
CHINA	10.01M	-	-
CHINA Growth	-	-	-
Swedan	5.18M	-	-
Swedan Growth	-	-	-

Frequently Asked Questions

Growth & Financials

Kazia Therapeutics Limited (KZIA) reported $2.5M in revenue for fiscal year 2025. This represents a 2% increase from $2.5M in 2012.

Kazia Therapeutics Limited (KZIA) saw revenue decline by 98.2% over the past year.

Kazia Therapeutics Limited (KZIA) reported a net loss of $44.1M for fiscal year 2025.

Dividend & Returns

Kazia Therapeutics Limited (KZIA) had negative free cash flow of $20.1M in fiscal year 2025, likely due to heavy capital investments.